The known-unknown: third- and fourth-generation cephalosporins combined with sulbactam

Author:

Stetsiouk O.U.1ORCID,Kovalenko T.N.2,Andreeva I.V.1ORCID,Belkova Yu.A.1

Affiliation:

1. Institute of Antimicrobial Chemotherapy (Smolensk, Russia)

2. Smolensk State Medical University (Smolensk, Russia)

Abstract

Despite the presence of more than 100 different antibacterials in the therapeutic arsenal, beta-lactam antibiotics, in general, and the third-generation cephalosporins, in particular, remain the main option for the treatment of the most of infections in inpatients. At the same time, the widespread and oftentimes inappropriate use of the third-generation cephalosporins in Russian hospitals lead to the emergence and spread of antimicroabial resistance. The review covers the problems of antibiotic resistance to cephalosporins due to the production of beta-lactamases, the role of beta-lactamase inhibitors in overcoming this type of resistance, options for combinations of cephalosporins with beta-lactamase inhibitors, in vitro activity of cefotaxime/sulbactam and cefepime/sulbactam, the results of clinical studies, and the role of the above combinations in the treatment of infections in the hospital.

Publisher

Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),Epidemiology

Reference48 articles.

1. Stetsiouk O.U., Andreeva I.V. Modern principles of antibacterial therapy of severe and life threatening bacterial infections. Farmateka. 2008;4:1217.

2. Bush K., Bradford P.A. β-Lactams and β-Lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8):a025247. DOI: 10.1101/cshperspect.a02524

3. Bush K. Past and present perspectives on β-lactamases. Antimicrob Agents Chemother. 2018;62(10): e01076-e01018. DOI: 10.1128/AAC.01076-18

4. Kozlov R.S., Stetsiouk O.U., Andreeva I.V. Current trends in antibiotic resistance of nosocomial infection pathogens in the Russian ICU: what's coming next? Intensivnaja terapija. 2007;4:217-227.

5. Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev. 1988;1(1):109-123. DOI: 10.1128/CMR.1.1.109

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3